A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study. (November 2022)

• Record Type: Journal Article
• Authors: Miglietta, F.; Ragazzi, M.; Fernandes, B.; Griguolo, G.; Massa, D.; Bisagni, A.; Bottosso, M.; Porra, F.; Gaudio, M.; Iannaccone, D.; Fassan, M.; Lo Mele, M.; Gasparini, E.; Zarrilli, G.; Coiro, S.; Dore, L.; Zambelli, A.; Bisagni, G.; Guarneri, V.; Dieci, M.V.
• Is Part Of: European journal of cancer. Volume 175(2022)Supplement 1
• Page Start: S3
• Publication Date: 2022-11
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(22)01354-5
• Languages: English
• ISSNs: 0959-8049